Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Multicenter Study of Hematopoietic Stem Cell Transplant of ECT-001-Expanded Cord Blood With a Reduced Toxicity Conditioning Regimen in Patients With Severe Sickle Cell Disease

NCT04594031 is registered in ClinicalTrials.gov with ExCellThera inc. as lead sponsor.

NCT NCT04594031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04594031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Multicenter Study of Hematopoietic Stem Cell Transplant of ECT-001-Expanded Cord Blood With a Reduced Toxicity Conditioning Regimen in Patients With Severe Sickle Cell Disease
Lead sponsor
ExCellThera inc.
Phase
Phase 1
Overall status
Withdrawn
Start date
July 13, 2021
Completion date
February 2, 2024
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic cell proliferation, sickle cell disease, umbilical cord blood